{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"AstraZeneca's Q1 2025 Financial Results - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"7PIP6rFcQd\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-q1-2025-financial-results\/\">AstraZeneca&#8217;s Q1 2025 Financial Results<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-q1-2025-financial-results\/embed\/#?secret=7PIP6rFcQd\" width=\"600\" height=\"338\" title=\"&#8220;AstraZeneca&#8217;s Q1 2025 Financial Results&#8221; &#8212; Market Newsdesk\" data-secret=\"7PIP6rFcQd\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"AstraZeneca&#8217;s Q1 2025 Financial Results Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211; AstraZeneca: Revenue and EPS summary \u00a0 Q1 2025 % Change \u00a0 \u00a0 \u00a0 $m Actual CER1 \u00a0 \u00a0 \u00a0 &#8211; Product Sales 12,875 6 9 \u00a0 \u00a0 \u00a0 &#8211; Alliance Revenue 639 40 42 \u00a0 \u00a0 \u00a0 Product Revenue2 13,514 7 10 \u00a0 \u00a0 \u00a0 Collaboration Revenue 74 64 64 \u00a0 \u00a0 \u00a0 Total Revenue 13,588 7 10 \u00a0 \u00a0 \u00a0 Reported EPS ($) 1.88 34 32 \u00a0 \u00a0 \u00a0 Core3EPS($) 2.49 21 21 \u00a0 \u00a0 \u00a0 Key performance elements for Q1 2025 (Growth numbers at constant exchange rates) Total Revenue up 10% to $13,588m, driven by double-digit &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250428918895r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}